Geode Capital Management LLC Purchases 1,138 Shares of XOMA Co. (NASDAQ:XOMA)

Geode Capital Management LLC grew its position in XOMA Co. (NASDAQ:XOMA) by 0.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 182,741 shares of the biotechnology company’s stock after purchasing an additional 1,138 shares during the period. Geode Capital Management LLC’s holdings in XOMA were worth $4,840,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in XOMA. Bank of New York Mellon Corp increased its position in XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after buying an additional 1,968 shares during the period. Rhumbline Advisers grew its stake in shares of XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after acquiring an additional 1,334 shares in the last quarter. Ellsworth Advisors LLC bought a new position in XOMA during the third quarter worth about $516,000. BNP Paribas Financial Markets boosted its holdings in XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 795 shares during the period. Finally, State Street Corp boosted its holdings in XOMA by 1.2% in the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after purchasing an additional 1,754 shares during the period. 95.92% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently weighed in on XOMA. HC Wainwright reiterated a “buy” rating and issued a $123.00 price target on shares of XOMA in a research report on Friday, December 13th. StockNews.com cut XOMA from a “hold” rating to a “sell” rating in a report on Friday, December 27th.

XOMA Price Performance

Shares of NASDAQ:XOMA opened at $26.82 on Friday. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $316.02 million, a PE ratio of -7.71 and a beta of 0.88. The firm has a 50 day moving average of $29.49 and a 200-day moving average of $27.90. XOMA Co. has a 12 month low of $18.57 and a 12 month high of $35.00.

Insider Buying and Selling at XOMA

In other news, CEO Owen Hughes sold 21,881 shares of XOMA stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the transaction, the chief executive officer now owns 34,979 shares in the company, valued at approximately $1,047,621.05. This trade represents a 38.48 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 7.20% of the company’s stock.

XOMA Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.